Inogen Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Inogen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INGN, but not buy additional shares or sell existing shares.
View analyst ratings for Inogen or view top-rated stocks.

Wall Street analysts have given Inogen a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Inogen wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Inogen saw a decline in short interest in February. As of February 12th, there was short interest totaling 921,600 shares, a decline of 19.2% from the January 28th total of 1,140,000 shares. Based on an average daily trading volume, of 163,100 shares, the days-to-cover ratio is currently 5.7 days. Approximately 5.0% of the company's shares are short sold.
View Inogen's Short Interest.

Inogen is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Inogen.

Inogen, Inc. (NASDAQ:INGN) announced its quarterly earnings data on Wednesday, February, 24th. The medical technology company reported ($0.23) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.28) by $0.05. Inogen had a positive trailing twelve-month return on equity of 0.21% and a negative net margin of 0.66%.
View Inogen's earnings history.

Inogen's stock was trading at $40.61 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, INGN stock has increased by 30.9% and is now trading at $53.14.
View which stocks have been most impacted by COVID-19.

4 equities research analysts have issued 12 month target prices for Inogen's shares. Their forecasts range from $54.00 to $75.00. On average, they expect Inogen's stock price to reach $63.00 in the next year. This suggests a possible upside of 18.6% from the stock's current price.
View analysts' price targets for Inogen or view top-rated stocks among Wall Street analysts.

70 employees have rated Inogen CEO Scott Wilkinson on Glassdoor.com. Scott Wilkinson has an approval rating of 46% among Inogen's employees. This puts Scott Wilkinson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Inogen include Avanos Medical (AVNS), Eargo (EAR), Establishment Labs (ESTA), Sientra (SIEN), Invacare (IVC), Lakeland Industries (LAKE), United Health Products (UEEC), Milestone Scientific (MLSS), Sanara MedTech (SMTI), Surgalign (SRGA), Alpha Pro Tech (APT), Nutriband (NTRB), Conformis (CFMS), ReWalk Robotics (RWLK) and CollPlant Biotechnologies (CLGN).
View all of INGN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Inogen investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Incyte (INCY), (MDVN) (MDVN), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), First Solar (FSLR), Intel (INTC) and Netflix (NFLX).

Inogen trades on the NASDAQ under the ticker symbol "INGN."

Inogen's stock is owned by many different retail and institutional investors. Top institutional shareholders include Brown Capital Management LLC (17.96%), BlackRock Inc. (14.03%), SummerHaven Investment Management LLC (2.34%), Dimensional Fund Advisors LP (2.17%), Bamco Inc. NY (2.11%) and Renaissance Technologies LLC (1.34%). Company insiders that own Inogen stock include Alison Bauerlein, Brenton Taylor, Heath Lukatch and Loren L Mcfarland.
View institutional ownership trends for Inogen.

INGN stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Renaissance Technologies LLC, Assenagon Asset Management S.A., Engineers Gate Manager LP, Matarin Capital Management LLC, Voloridge Investment Management LLC, Bank of New York Mellon Corp, and Hunter Associates Investment Management LLC. Company insiders that have sold Inogen company stock in the last year include Alison Bauerlein, and Brenton Taylor.
View insider buying and selling activity for Inogen or view top insider-selling stocks.

INGN stock was acquired by a variety of institutional investors in the last quarter, including SummerHaven Investment Management LLC, Bamco Inc. NY, JPMorgan Chase & Co., BlackRock Inc., Morgan Stanley, Brown Capital Management LLC, Riverbridge Partners LLC, and Gyon Technologies Capital Management LP. Company insiders that have bought Inogen stock in the last two years include Heath Lukatch, and Loren L Mcfarland.
View insider buying and selling activity for Inogen or or view top insider-buying stocks.

Shares of INGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INGN stock can currently be purchased for approximately $53.14.

Inogen has a market capitalization of $1.18 billion and generates $361.94 million in revenue each year. The medical technology company earns $20.95 million in net income (profit) each year or $1.07 on an earnings per share basis.

Inogen employs 1,020 workers across the globe.

The official website for Inogen is www.inogen.com.

Inogen is headquartered at 326 BOLLAY DRIVE, GOLETA CA, 93117.

Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company can be reached via phone at 805-562-0500 or via email at [email protected]